{"ATC Code":"N05AD01","Abbreviation":[],"Aliases":["Serenace","Aloperidin","Eukystol","Brotopon","Serenase","Serenelfi","Linton","Dozic","Einalon S","Aloperidolo","Galoperidol","Halopoidol","Halopal","Keselan","Ulcolind","Uliolind","Pernox","Sernas","Sernel","Aldo","Bioperidolo","Sigaperidol","Peluces","Haldol Solutab","Haloperidolum"],"Biological Half-Life":"Following oral administration, the half-life was found to be 14.5-36.7 hours. Following intramuscular injection, mean half-life was found to be 20.7 hours.","CAS":"52-86-8","ChEBI":"CHEBI:5613","ChEMBL":"CHEMBL54","ChemicalClasses":[],"Chirality":"achiral","Color/Form":"Crystals","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents; Butyrophenones","Drug Indication":"Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also indicated in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics.","Drug Warnings":"Pregnancy risk category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./","EINECS":"200-155-6","Erowid Experience Reports":[{"Author":"Friend from Colorado","Id":"116293","Title":"Not for Recreational Use in Any Way"}],"Esters":[],"European Community (EC) Number":"200-155-6","FDA Pharmacological Classification":"J6292F8L3D","Formating":[],"HMDB ID":"HMDB0014645","HeavyAtomCount":26,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents; Butyrophenones","IUPACName":"4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one","InChI":"InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","InChIKey":"LNEPOXFFQSENCJ-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)","Melting Point":"151.5 °C","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e23\u003c/sub\u003eClFNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"375.9 g/mol","Pharmacodynamics":"Use of the first-generation antipsychotics (including haloperidol) is considered highly effective for the management of the \"positive\" symptoms of schizophrenia including hallucinations, hearing voices, aggression/hostility, disorganized speech, and psychomotor agitation. However, this class is limited by the development of movement disorders such as drug-induced parkinsonism, akathisia, dystonia, and tardive dyskinesia, and other side effects including sedation, weight gain, and prolactin changes. Compared to the lower-potency first-generation antipsychotics such as [DB00477], [DB01624], [DB00623], and [DB01403], haloperidol typically demonstrates the least amount of side effects within class, but demonstrates a stronger disposition for causing extrapyramidal symptoms (EPS). Low‐potency medications have a lower affinity for dopamine receptors so that a higher dose is required to effectively treat symptoms of schizophrenia. In addition, they block many receptors other than the primary target (dopamine receptors), such as cholinergic or histaminergic receptors, resulting in a higher incidence of side effects such as sedation, weight gain, and hypotension.  The balance between the wanted drug effects on psychotic symptoms and unwanted side effects are largely at play within dopaminergic brain pathways affected by haloperidol. Cortical dopamine-D2-pathways play an important role in regulating these effects and include the nigrostriatal pathway, which is responsible for causing extrapyramidal symptoms (EPS), the mesolimbic and mesocortical pathways, which are responsible for the improvement in positive schizophrenic symptoms, and the tuberoinfundibular dopamine pathway, which is responsible for hyperprolactinemia.   A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.  Cases of sudden death, QT-prolongation, and Torsades de Pointes have been reported in patients receiving haloperidol. Higher than recommended doses of any formulation and intravenous administration of haloperidol appear to be associated with a higher risk of QT-prolongation and Torsades de Pointes. Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other QT-prolonging conditions (including electrolyte imbalance [particularly hypokalemia and hypomagnesemia], drugs known to prolong QT, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome).  A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.","Physical Description":"Solid","PubChemId":3559,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Haloperidol","Name":"Haloperidol","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00502","Name":"Haloperidol","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3559","Name":"Haloperidol","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL54","Name":"Haloperidol","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5613","Name":"Haloperidol","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=52-86-8","Name":"Haloperidol","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014645","Name":"Haloperidol","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C01814","Name":"Haloperidol","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/J6292F8L3D","Name":"Haloperidol","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4034150","Name":"Haloperidol","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3559, Haloperidol. Accessed July 27, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3559\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3559\u003c/a\u003e"],"SMILES":"C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F","SaltData":[],"Salts":[],"Solubility":"23.5 [ug/mL] (The mean of the results at pH 7.4)","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 199.373 66.127\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h200v67H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m78.645 56.354 13.198-7.62M91.843 48.734l-.003-11.399M88.686 31.664l-10.051-5.807M78.635 25.857l-13.198 7.62M65.437 33.477l.005 15.248M78.645 56.354l-13.203-7.629M65.442 48.725l-15.009-2.644\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m50.433 46.081-5.176-14.156M47.658 45.592l-4.211-11.518\"/\u003e\u003c/g\u003e\u003cpath d=\"m45.257 31.925-14.995-2.721\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m30.262 29.204-9.919 11.418M31.192 31.851l-8.07 9.29\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.343 40.622 5.222 14.474\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m25.565 55.096 14.995 2.72M27.382 52.948l12.222 2.217\"/\u003e\u003c/g\u003e\u003cpath d=\"M50.433 46.081 40.56 57.816M20.343 40.622 7.039 38.139M65.442 48.725l-3.848 10.571M94.992 31.665l10.045-5.8M105.037 25.865l13.198 7.62M118.235 33.485l13.198-7.62M131.433 25.865l13.199 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M145.851 32.782v12.022M143.412 32.782v12.022\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M145.851 44.804v-6.011M143.412 44.804v-6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m144.632 33.485 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m157.832 10.625-.002 15.24M160.27 12.034l-.002 12.424\"/\u003e\u003c/g\u003e\u003cpath d=\"m157.832 10.625 13.209-7.617\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m184.248 10.63-13.207-7.622M181.81 12.038l-10.769-6.215\"/\u003e\u003c/g\u003e\u003cpath d=\"m184.248 10.63-.002 15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m171.037 33.488 13.209-7.618M171.037 30.672l10.771-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m157.83 25.865 13.207 7.623M184.248 10.63l10.62-6.131\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M93.779 35.935h-.72l-2.619-4.066h-.03l.03.596q.023.357.023.732v2.738h-.565v-4.899h.714l2.608 4.054h.029l-.017-.328-.024-.476q-.006-.262-.006-.482v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M2.906 36.011q-.786 0-1.239.529-.452.524-.452 1.447 0 .911.417 1.447.422.529 1.268.529.321 0 .607-.053.292-.06.565-.143v.536q-.273.101-.565.149-.292.053-.697.053-.744 0-1.25-.309-.5-.31-.75-.875-.25-.572-.25-1.34 0-.744.268-1.31.274-.565.804-.881.529-.321 1.279-.321.78 0 1.352.286l-.244.523q-.226-.101-.506-.184-.274-.083-.607-.083m2.756 4.423h-.601v-5.215h.601z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M62.487 63.043q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .923.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M57.407 65.496h-.619V63.21h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M146.891 48.723q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.566.756-.881t1.274-.316q.733 0 1.233.316.5.309.756.875t.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M196.693 5.459h-.613V.56h2.733v.542h-2.12V2.84h1.995v.542h-1.995z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m91.84 37.335.001 5.7M88.686 31.664l-5.025-2.903\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m7.039 38.139 6.652 1.241\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m61.594 59.296 1.924-5.285M61.594 59.296l1.924-5.285\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m94.992 31.665 5.022-2.9\" class=\"hi\"/\u003e\u003cpath stroke=\"#90e050\" d=\"m194.868 4.499-5.31 3.066\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Anti-Dyskinesia Agents; Antiemetics; Antipsychotic Agents, Butyrophenone; Dopamine Antagonists","Title":"Haloperidol","UNII":"J6292F8L3D","Wikipedia":"Haloperidol","XLogP":3.2}